Grupo Espanol De Tumores Neuroendocrinos

This study is testing a new drug called tarlatamab for people with advanced neuroendocrine cancer of the digestive system or unknown origin. The trial will see if the drug works better by itself or when combined with standard chemotherapy. It aims to help patients whose cancer ha…

This study aims to see if a new targeted radiation treatment (177Lu-edotreotide) works better than the standard pill (everolimus) for people with advanced neuroendocrine tumors in the lungs or thymus gland. It will involve about 120 adults whose tumors have grown despite prior tr…

This study is for people with a specific type of slow-growing digestive tract cancer. It is testing if giving the same radioactive drug treatment less often (every 16 weeks instead of every 8 weeks) can cause fewer serious side effects, especially blood-related problems, while st…